Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-3434

Next Previous
Search
Trial Profile

A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-3434

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tobevibart (Primary) ; Tobevibart (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Vir Biotechnology

    • Most Recent Events

    • 14 Nov 2023 Initial results (n=18) assessing immune complex (IC) detection in participants with CHB given a single dose of VIR-3434 in Parts B-D were presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 24 Jun 2023 Results (n=72) assessing VIR-3434 pharmacokinetics(PK) after single dose administration in participants with chronic HBVinfection presented at the European Association for the Study of the Liver Congress 2023
    • 16 Dec 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top